Related Experiment Video

Updated: Aug 25, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Atorvastatin in dyslipidaemia of the nephrotic syndrome

Pedro Valdivielso1, Manuel Moliz, Alfonso Valera

  • 1Department of Internal Medicine, Nephrology and Lipid Unit, Hospital Clínico Universitario Virgen de la Victoria, Servicio Andaluz de Salud y Universidad de Málaga, Málaga, Spain. valdivielso@uma.es

Nephrology (Carlton, Vic.)
|March 12, 2004
PubMed

Insights

Low-dose atorvastatin effectively manages dyslipidaemia in nephrotic syndrome patients, reducing cardiovascular risk. This study found atorvastatin safe, well-tolerated, and even beneficial for renal function, decreasing proteinuria.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Nephrotic syndrome is associated with dyslipidaemia, increasing cardiovascular risk and potentially worsening renal function.
  • Effective management of dyslipidaemia is crucial for improving outcomes in patients with nephrotic syndrome.

Purpose of the Study:

  • To evaluate the efficacy and safety of 10 mg atorvastatin in controlling dyslipidaemia in patients with nephrotic syndrome.
  • To assess the impact of atorvastatin on lipid profiles, safety parameters, and renal function.

Main Methods:

  • A prospective, open-label, 6-month study involving 10 patients with nephrotic syndrome.
  • Patients received 10 mg of atorvastatin daily, with measurements of lipids, lipoproteins, safety markers, and renal function.

Main Results:

  • Atorvastatin significantly reduced LDL cholesterol by 41% and triglycerides by 31% (P < 0.05).
  • HDL cholesterol increased by 15% (NS).
  • The drug was well-tolerated, with no adverse effects on safety markers or renal function; proteinuria decreased in most patients.

Conclusions:

  • Low-dose atorvastatin (10 mg daily) is a safe and effective treatment for dyslipidaemia in nephrotic syndrome.
  • Atorvastatin therapy may also offer renal benefits by reducing proteinuria in these patients.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...